Iambic Therapeutics (NASDAQ:IAM – Get Free Report) posted its earnings results on Monday. The company reported ($6.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($5.90), Zacks reports.
Iambic Therapeutics Trading Down 5.3%
Iambic Therapeutics stock traded down $0.70 during mid-day trading on Monday, reaching $12.40. 62,073 shares of the stock traded hands, compared to its average volume of 702,201. Iambic Therapeutics has a 12-month low of $9.60 and a 12-month high of $25.00.
Insiders Place Their Bets
In other news, Director Evan Lockwood Rachlin bought 718,750 shares of the company’s stock in a transaction on Friday, October 16th. The shares were acquired at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the completion of the transaction, the director owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. This trade represents a 38.45% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Analysts Set New Price Targets
Several research firms recently commented on IAM. JPMorgan Chase & Co. started coverage on Iambic Therapeutics in a research report on Monday, November 9th. They set an “overweight” rating and a $22.00 price objective on the stock. Zacks Research started coverage on Iambic Therapeutics in a report on Tuesday, November 10th. They issued a “hold” rating for the company. Citigroup started coverage on Iambic Therapeutics in a research report on Monday, November 9th. They issued a “buy” rating and a $22.00 target price for the company. Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. Finally, Bank of America initiated coverage on shares of Iambic Therapeutics in a report on Monday, November 9th. They set a “buy” rating and a $30.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Iambic Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $27.25.
Check Out Our Latest Report on IAM
Iambic Therapeutics Company Profile
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
Featured Articles
- Five stocks we like better than Iambic Therapeutics
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
